All In Biotech

NDA 019141 · Fougera

Betamethasone Dipropionate

Betamethasone Dipropionate · Topical

Last checked: Nov 19, 2026Latest source record: Jun 7, 1996 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Sep 4, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

30 Phase 3, 11 recruiting

FAERS reports

5,885

4,060 serious, 501 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2026.

INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 4, 1984 Original approval
1 products under this application
  • BETAMETHASONE DIPROPIONATE · BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · OINTMENT, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,406
  • off label use641
  • macular degeneration532
  • nausea497
  • psoriasis466
  • pruritus454
  • pain450
  • condition aggravated410
  • pain in extremity392
  • headache390
  • fatigue379
  • rash375

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200525
200618
200724
200822
200921
201016
201141
201250
201338
201448
201587
2016161
2017199
2018233
2019334
2020430
2021742
2022735
2023760
2024620
2025711
2026553

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Betamethasone Dipropionate (Betamethasone Dipropionate)

2024 spending

$33.0M

Beneficiaries

427,470

766,652 claims

Per beneficiary

$77

$0.93 per unit

View as table
YearSpending
2020$49,288,047
2021$47,547,573
2022$45,945,591
2023$42,156,509
2024$33,021,357

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 225 on PubMed

Sponsor: Fougera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.